内科

目的探讨乌司他丁联合胸腺肽治疗重症肺炎患者的临床效果。方法选择2018年5月至2019年5月我院收治的重症肺炎患者86例为研究对象，采用随机数字法分为两组，每组43例。对照组患者给予常规治疗，观察组患者在对照组患者治疗的基础上给予乌司他丁及胸腺肽治疗，疗程10 d。比较两组患者治疗前后的动脉血气分析结果、炎症指标水平以及急性生理学与慢性健康状况评分系统Ⅱ（APACHE Ⅱ）评分。结果治疗前，两组患者的动脉血氧分压（PaO2）、动脉血二氧化碳分压（PaCO2）和动脉血氧饱和度（SaO2）比较，差异无统计学意义（P＞0.05）；治疗10 d后，两组患者的PaO2、PaCO2、SaO2水平均显著升高，观察组患者的水平显著高于对照组，差异均有统计学意义（P＜0.05）。治疗前，两组患者的降钙素原、C反应蛋白（CRP）、血清淀粉样蛋白-A(SAA)和白介素6（IL-6）水平比较，差异无统计学意义（P＞0.05）；治疗10 d后，两组患者的降钙素原、CRP、SAA、IL-6水平均显著下降，观察组患者的水平显著低于对照组，差异均有统计学意义（P＜0.05）。治疗前，两组患者的APACHE Ⅱ评分比较，差异无统计学意义（P＞0.05）；治疗10 d后，两组患者的APACHE Ⅱ评分均显著降低，观察组患者的评分显著低于对照组，差异有统计学意义（P＜0.05）。结论在常规治疗的基础上，加用乌司他丁及胸腺肽治疗重症肺炎患者，可有效改善呼吸功能、显著降低炎症因子水平、明显减轻病情、改善预后，值得推广应用。

ObjectiveTo investigate the clinical effect of ulinastatin combined with thymosin in the treatment of severe pneumonia. MethodsA total of 86 patients with severe pneumonia admitted to our hospital from May 2018 to May 2019 were selected as the research objects, and they were assigned to two groups according to the random number method, with 43 cases in each group. The control group was given conventional treatment, based on which the observation group was given ulinastatin combined with thymosin for treatment, for a ten-day course of treatment. The pre-and post-treatment results of arterial blood gas analysis, inflammatory index levels, and acute physiology and chronic health evaluation Ⅱ(APACHE Ⅱ) system score were compared between the two groups. ResultsBefore treatment, there were no statistically significant differences in the arterial partial pressure of oxygen (PaO2), partial pressure of carbon dioxide in arterial blood (PaCO2) and arterial oxygen saturation (SaO2) between the two groups (P＞0.05). After 10 days of treatment, the levels mentioned above significantly increase, and the observation group yielded significantly higher levels as compared with the control group, with statistically significant differences (P＜0.05). Before treatment, there were no statistically significant differences in the levels of procalcitonin, C-reactive protein (CRP), serum amyloid-A (SAA) and interleukin 6 (IL-6) between the two groups (P＞0.05). After 10 days of treatment, the levels mentioned above significantly decreased, and the levels of the observation group were significantly lower than those of the control group, with statistically significant differences (P＜0.05). Before treatment, there was no statistically significant difference in the APACHE Ⅱ score between the two groups (P＞0.05). After 10 days of treatment, the APACHE Ⅱ score of the two groups significantly decreased, and the observation group yielded a lower score compared with the control group, with statistically significant differences (P＜0.05). ConclusionOn the basis of conventional treatment, additionally administration of ulinastatin and thymosin in treating patients with severe pneumonia can effectively improve the respiratory function, significantly decrease the levels of inflammatory factors, significantly alleviate the condition, and improve the prognosis, which is worthy of promotion and application.